NewAmsterdam Pharma Company N.V., a clinical-stage biopharmaceutical company, focuses on improving patient care in populations with metabolic diseases. Its lead investigational candidate, obicetrapib, is a novel, selective inhibitor that targets the Cholesteryl Ester Transfer Protein (CETP), which has been clinically shown to reduce low-density lipoprotein cholesterol (LDL-C) while at the same time substantially increase high-density lipoprotein cholesterol (HDL-C). The company was founded in 2019 and is based in Naarden, the Netherlands.
P/E ratio for NewAmsterdam Pharma Company N.V. (NAMS)
P/E ratio as of 2023: -5.19
According to NewAmsterdam Pharma Company N.V.'s latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -5.19. At the end of 2022 the company had a P/E ratio of -9.78.
P/E ratio history for NewAmsterdam Pharma Company N.V. from 2020 to 2023
PE ratio at the end of each year
| Year | P/E ratio |
|---|---|
| 2023 | -5.19 |
| 2022 | -9.78 |
| 2021 | -4.71 |
| 2020 | -32.77 |